NCT01271387View on ClinicalTrials.gov

Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Hepatic Impairment
Interventions
DRUG

tasimelteon

20 mg tasimelteon capsules, PO single dose

Trial Locations (1)

32809

Orlando Clinical Research Center, Orlando

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY